BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 19013348)

  • 1. Anidulafungin in the treatment of patients with invasive candidiasis.
    Kett DH; Cubillos GF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anidulafungin versus fluconazole for invasive candidiasis.
    Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
    N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Echinocandins in invasive candidiasis].
    Glöckner A; Cornely OA
    Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandins: The Expanding Antifungal Armamentarium.
    Aguilar-Zapata D; Petraitiene R; Petraitis V
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
    Estes KE; Penzak SR; Calis KA; Walsh TJ
    Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
    Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal resistance: the clinical front.
    Perfect JR
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of invasive candidiasis with echinocandins.
    Glöckner A; Steinbach A; Vehreschild JJ; Cornely OA
    Mycoses; 2009 Nov; 52(6):476-86. PubMed ID: 19076282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
    Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
    Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of invasive candidal infections: systematic review and meta-analysis.
    Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
    Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida endophthalmitis: focus on current and future antifungal treatment options.
    Khan FA; Slain D; Khakoo RA
    Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anidulafungin, a new echinocandin: effectiveness and tolerability.
    Menichetti F
    Drugs; 2009; 69 Suppl 1():95-7. PubMed ID: 19877741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anidulafungin--state of affairs from a clinical perspective.
    Vehreschild JJ; Kümmerle T; Karthaus M; Cornely OA
    Mycoses; 2007; 50 Suppl 1():38-43. PubMed ID: 17394608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.